Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Special Category — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category

Other

Neoplasm by Special Category

CI-CAN-00000004Explore in graph →

Non-malignant21,361 active trials259 approved drugs3,860 evidence items

NCIt: C7062

Overview
Statistics
Survival
Genomics477
Variants & evidence3860
Drugs429
Trials95753
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,576)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,901–3,925 of 4,576 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed
Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.
· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed
Upregulation of the antiapoptotic factor Livin contributes to cisplatin resistance in colon cancer cells.
· Tumour Biol · 2013 · PMID 23188704 · validated civic_curation pubmed
Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed
FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
· Clin Cancer Res · 2014 · PMID 24771645 · validated civic_curation pubmed
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.
· PLoS One · 2011 · PMID 21666749 · validated civic_curation pubmed
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
· Nature · 2015 · PMID 25409150 · validated civic_curation pubmed

Showing 3,901–3,925 of 4,576 publications

← Previous
1
…
156
157
158
…
184
Next →

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

· Science · 2007 · PMID 17463250 · validated civic_curation pubmed

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

· Nat Genet · 2009 · PMID 19718025 · validated civic_curation pubmed

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

· Cancer Cell · 2011 · PMID 21840482 · validated civic_curation pubmed

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

· Sci Transl Med · 2011 · PMID 21900593 · validated civic_curation pubmed

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.

· Mol Cancer · 2014 · PMID 24894453 · validated civic_curation pubmed

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

· Cancer Discov · 2012 · PMID 22961667 · validated civic_curation pubmed

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

· Cancer Cell · 2012 · PMID 22698404 · validated civic_curation pubmed

The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.

· Cancer Res · 2014 · PMID 25056119 · validated civic_curation pubmed

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

· Cell Cycle · 2014 · PMID 24841718 · validated civic_curation pubmed

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules.

· Br J Cancer · 2012 · PMID 22333600 · validated civic_curation pubmed

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

· Mol Cancer Ther · 2012 · PMID 22169769 · validated civic_curation pubmed

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

· Science · 2013 · PMID 23558169 · validated civic_curation pubmed

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.

· Cell Rep · 2014 · PMID 25199829 · validated civic_curation pubmed

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

· Cell Rep · 2014 · PMID 24685132 · validated civic_curation pubmed

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

· Cancer Cell · 2016 · PMID 26725216 · validated civic_curation pubmed

HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.

· Proc Natl Acad Sci U S A · 2009 · PMID 19122144 · validated civic_curation pubmed

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.

· Mol Cancer · 2014 · PMID 24898067 · validated civic_curation pubmed

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.

· Mol Cancer Ther · 2014 · PMID 24899684 · validated civic_curation pubmed